BOSTON, Massachusetts, June 9, 2025; Leksum LLC ("Leksum") has partnered with the Department of Clinical Sciences, SLU, Uppsala, Sweden ("SLU") to host Leksum's one-of-a-kind muscle research lab. It will be headed by Lars Larsson, MD/PhD, Leksum's Chief Scientific Officer, one of the world's leading researchers in muscle science. The lab is a unique experimental ICU model not limited by early mortality. Leksum's scientific team leverages the lab to understand the mechanism underlying the loss of muscle mass and function coupled with myosin modifications and preferential myosin loss. No other lab in the world can do the long-term mechanistic and intervention studies required for substantive muscle studies under ICU conditions, which require immobilization and mechanical ventilation ("MV").
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Leksum LLC has relocated its laboratory to SLU in Uppsala, Sweden, under the leadership of renowned muscle scientist Professor Lars Larsson, to advance research on ICU-related muscle myopathies.
- The lab features a unique ICU model capable of long-term studies not limited by early mortality, enabling unprecedented mechanistic and therapeutic research into muscle degradation caused by immobilization and mechanical ventilation.
- The partnership between Leksum and SLU establishes a global hub for pioneering treatments targeting acquired muscle myopathies, with the potential for both preventative and therapeutic clinical applications.
Click image above to view full announcement.
Leksum LLC, based in Boston, Massachusetts with its primary laboratory at SLU, Uppsala, Sweden, is an early-stage life sciences company developing advanced biologic therapies to address acquired muscle myopathies. The company is preparing to enter into Phase I/IIa studies related to its LK-ICU program, which encompasses therapies addressing muscle myopathies resulting from the use of mechanical ventilation in ICUs, in particular with immobilized patients. Leksum's scientific team is also researching additional skeletal muscle conditions including sarcopenia, cancer cachexia, and muscle-loss due to the use of weight-loss drugs (i.e., GLP-1s).
About SLU
SLU (Swedish University of Agricultural Sciences), Department of Clinical Sciences, located in Uppsala, Sweden, conducts education, research and environmental monitoring and assessment in collaboration with society at large. Through its focus on the interaction between humans, animals and ecosystems and the responsible use of natural resources, it contributes to sustainable societal development and good living conditions on our planet.
Contacts:
Niles Chura, CEO, Leksum LLC
[email protected]
Source: Leksum
Distributed by: Reportable, Inc.
